A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants with Cancer Harboring BRAF Alterations
| ClinicalTrials.gov Identifier |
| NCT05503797 |
| Principal Investigator |
| N/A |
| Principal Investigator Phone |
| N/A |
| Principal Investigator Email |
| N/A |
| Study Coordinator |
| See full list below |
| Study Coordinator Phone |
| See full list below |
| Study Coordinator Email |
| See full list below |
| Additional Study Coordinators |
|
For additional locations please see https://clinicaltrials.gov/study/NCT05503797 California - Los Angeles University of California Los Angeles Rheumatology - Westwood Johnathan Flores johnflores@mednet.ucla.edu California - San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Robert Castillo robert.castillo@ucsf.edu Florida - Miami University of Miami Hospital and Clinics Maria Diaz Alonso mmd220@med.miami.edu Maryland - Baltimore The Johns Hopkins Hospital Erin Dailey erin.dailey@umm.edu Maryland - Columbia Maryland Oncology Hematology - Columbia Shakyra Tyus shakyra.tyus@usoncology.com Massachusetts - Boston Tufts Medical Center Jill Marshall jill.marshall@tuftsmedicine.org Minnesota - Duluth St. Luke's Hospital - Duluth Charity Gonzalez charity.gonzalez@aspirus.org Missouri - Saint Louis Chirosree Bandyopadhyay bandyc@fredhutch.org Missouri - St. Joseph Mosaic Life Care at Saint Joseph - Medical Center Monica Morrill monica.morrill@mymlc.com Nebraska - Grand Island Nebraska Cancer Specialists - Midwest Cancer Center - Legacy Brenda Broekemeier bbroekemeier@nebraskacancer.com New Jersey - Morristown Overlook Medical Center Christopher Buck christopher.buck@atlantichealth.org New York - New York Columbia University Irving Medical Center Karishma Sookraj kss2158@cumc.columbia.edu New York - New York Memorial Sloan Kettering Cancer Center - New York Susan Korte kortes@mskcc.org Ohio - Columbus Nationwide Children's Hospital Brittany Konkle brittany.konkle@nationwidechildrens.org Ohio - Toledo Taylor Cancer Research Center Jessica Obarski jobarski@tcrcpt.org Pennsylvania - Philadelphia Thomas Jefferson University - Center City Rachel Kane rachel.kane2@jefferson.edu Rhode Island - Providence Lifespan Cancer Institute - Rhode Island Hospital William Siwik wsiwik@lifespan.org Texas - Dallas Baylor Scott & White Research Institute Chinwe Onyekonwu chinwendu.onyekonwu@bswhealth.org Texas - Temple, TX Baylor Scott & White Medical Center - Temple Kharren Woods kharren.woods@bswhealth.org Washington - Seattle University of Washington School of Medicine Hannah Lee hpiek@fredhutch.org West Virginia - Morgantown, WV West Virginia University Health Sciences Campus Nina Moore nina.moore@hsc.wvu.edu |
| Study Overview |
| The purpose of this study is to assess the efficacy and safety of plixorafenib in participants with cancer, including cholangiocarcinoma, who have alterations in a gene called BRAF. |
| Enrollment Information |
| Approximately 250 |
| Study Start Date |
| 2023-02-21 |
| Study End Date |
| 2026-08-28 |
| Financial Assistance Available |
| Yes |